Toxicology – Methemoglobinemia

Definition

Methemoglobinemia occurs when hemoglobin iron is oxidized from its normal ferrous (Fe²⁺) state to the ferric (Fe³⁺) state.

Ferric hemoglobin, called methemoglobin (MetHb), cannot effectively bind oxygen.

Normally, MetHb represents approximately <1–2% of total hemoglobin.

Pathophysiology

Methemoglobinemia impairs oxygen delivery by two mechanisms:

1. Methemoglobin itself cannot carry oxygen effectively.
2. Methemoglobin increases the oxygen affinity of the remaining normal hemoglobin, shifting the oxyhemoglobin dissociation curve to the left.

Therefore:

Oxidation of Fe²⁺ → Fe³⁺ → reduced O₂-carrying capacity + impaired O₂ unloading → tissue hypoxia

This produces a form of functional anemia despite a potentially normal measured hemoglobin concentration and PaO₂.

Normal Reduction of Methemoglobin

Small amounts of methemoglobin are continuously generated and normally converted back to functional hemoglobin.

The major pathway uses:

Cytochrome b₅ reductase (NADH-dependent methemoglobin reductase)

A secondary NADPH-dependent pathway normally contributes little but becomes clinically important when methylene blue is administered.

Methylene Blue Mechanism

Methylene blue acts as an electron carrier.

In the presence of NADPH, it is converted to leucomethylene blue, which accelerates reduction of:

Fe³⁺ → Fe²⁺

NADPH production depends heavily on the pentose phosphate pathway and G6PD, explaining why methylene blue may be ineffective or harmful in significant G6PD deficiency.

Causes

Most acquired cases result from exposure to an oxidizing medication or chemical.

Important causes include:

• Benzocaine
• Prilocaine
• Dapsone
• Nitrates
• Nitrites
• Amyl/alkyl nitrites
• Aniline compounds
• Phenazopyridine
• Primaquine
• Sulfonamides
• Nitroglycerin and related nitrates
• Some industrial oxidizing chemicals

Benzocaine and dapsone are particularly important toxicologic causes.

Dapsone

Dapsone is notable because its metabolites are potent oxidants.

Toxicity may produce:

• Significant methemoglobinemia
• Hemolysis
• Recurrent or prolonged methemoglobinemia

Because of its pharmacokinetics and enterohepatic/enteric recycling, clinically important methemoglobinemia can recur after initial improvement.

Nitrites and Nitrates

Nitrites directly oxidize hemoglobin.

Nitrates can be converted to nitrites and may therefore produce methemoglobinemia.

Potential exposures include:

• Contaminated water
• Certain foods or chemicals
• Medications
• Recreational inhaled nitrites

Infants are particularly susceptible.

Infants

Young infants have increased susceptibility because:

• Fetal hemoglobin is more readily oxidized.
• Methemoglobin-reducing enzyme activity is relatively immature.
• Certain gastrointestinal conditions may increase nitrite production.

Thus, relatively modest oxidant exposure may cause more clinically important methemoglobinemia in infants.

Congenital Methemoglobinemia

Congenital causes include:

• Cytochrome b₅ reductase deficiency
• Hemoglobin M variants

Patients with congenital disease may have chronic cyanosis despite otherwise relatively few symptoms, depending on the specific disorder.

G6PD Deficiency

G6PD deficiency does not represent the usual mechanism of methemoglobinemia itself, but it is extremely important when choosing treatment.

Reduced G6PD activity limits production of NADPH.

Consequently, methylene blue may:

• Work poorly
• Increase oxidative stress
• Cause or worsen hemolysis

Significant G6PD deficiency therefore complicates treatment.

Clinical Features

Symptoms depend on:

• Methemoglobin concentration
• Rate of development
• Baseline hemoglobin
• Cardiopulmonary reserve
• Other causes of impaired oxygen delivery

Common manifestations include:

• Cyanosis
• Headache
• Fatigue
• Dizziness
• Dyspnea
• Tachycardia
• Tachypnea

More severe toxicity may cause:

• Confusion
• Syncope
• Chest pain
• Hypotension
• Dysrhythmias
• Seizures
• Coma
• Cardiovascular collapse

Cyanosis

Cyanosis is one of the classic findings.

It is often described as slate-gray, blue-gray, or brownish and may persist despite supplemental oxygen.

A patient with:

Persistent cyanosis + relatively preserved PaO₂ + unusual pulse-oximetry findings

should raise strong suspicion for dyshemoglobinemia.

Chocolate-Brown Blood

Blood containing substantial methemoglobin may appear dark or chocolate brown rather than normally bright red.

This appearance is a useful clue but does not replace laboratory confirmation.

Severity and MetHb Level

Symptoms generally become more likely as the MetHb percentage rises, but rigid concentration thresholds are unreliable.

Broadly:

• Low levels: often asymptomatic
• Moderate levels: cyanosis, headache, dizziness, fatigue, dyspnea
• Higher levels: confusion, syncope, chest pain, marked hypoxia symptoms
• Severe levels: seizures, dysrhythmias, shock, coma
• Very high levels: potentially fatal

Treatment should therefore be based on the patient’s symptoms, MetHb concentration, underlying disease, and ongoing oxidant exposure, rather than concentration alone.

Higher-Risk Patients

Symptoms can develop at lower MetHb concentrations in patients with:

• Anemia
• Coronary artery disease
• Heart failure
• Significant pulmonary disease
• Sepsis or shock
• Other conditions reducing oxygen delivery

Pregnancy and infancy also warrant particular caution.

Pulse Oximetry

Standard two-wavelength pulse oximetry is unreliable in methemoglobinemia.

As MetHb rises, the displayed oxygen saturation tends to drift toward approximately the mid-80% range, often around 85%, regardless of the actual arterial oxygen content.

Thus, an SpO₂ that remains near the mid-80s despite oxygen therapy is a classic clue.

PaO₂ Can Be Normal

A major diagnostic pitfall is assuming that a normal arterial PaO₂ excludes serious hypoxia.

PaO₂ measures oxygen dissolved in plasma.

It does not directly measure how much oxygen hemoglobin is actually carrying.

Therefore:

Methemoglobinemia → normal/high PaO₂ may coexist with severely impaired hemoglobin-mediated oxygen delivery

Saturation Gap

A saturation gap may occur when:

• Calculated arterial oxygen saturation from a blood gas appears normal or high,
• while pulse oximetry shows substantially lower saturation.

This discrepancy should raise suspicion for a dyshemoglobinemia such as:

• Methemoglobinemia
• Carboxyhemoglobinemia

However, direct co-oximetry is preferred for diagnosis.

Co-Oximetry

Co-oximetry is the diagnostic test of choice.

Unlike ordinary pulse oximetry, it uses multiple wavelengths to distinguish:

• Oxyhemoglobin
• Deoxyhemoglobin
• Methemoglobin
• Carboxyhemoglobin

The MetHb percentage should therefore be directly measured, not inferred from standard oxygen saturation.

Evaluation

Important investigations include:

• Co-oximetry with MetHb measurement
• ECG
• CBC
• Electrolytes
• Renal function
• Blood gas when clinically indicated

Depending on severity or suspected toxicant:

• Lactate
• Hemolysis studies
• Liver tests
• Targeted toxicology testing

G6PD testing may be useful but generally should not delay emergency management.

Hemolysis

Some oxidant exposures can cause both:

• Methemoglobinemia
• Oxidative hemolytic anemia

This is particularly relevant with agents such as:

• Dapsone
• Naphthalene
• Primaquine
• Other strong oxidants

Evidence of hemolysis may include:

• Falling hemoglobin
• Elevated bilirubin
• Elevated LDH
• Reduced haptoglobin
• Abnormal peripheral smear

Initial Management

The first steps are:

• Stop exposure to the causative agent.
• Support airway and ventilation as necessary.
• Administer supplemental oxygen.
• Obtain co-oximetry.
• Assess for cardiovascular or neurologic evidence of tissue hypoxia.

Supplemental oxygen does not directly convert methemoglobin back to normal hemoglobin, but it maximizes oxygenation of the remaining functional hemoglobin.

Methylene Blue

Methylene blue is the standard antidote for clinically significant acquired methemoglobinemia.

It is particularly considered when there is:

• Significant symptomatic methemoglobinemia
• Neurologic dysfunction
• Cardiovascular manifestations
• Significant or rising MetHb concentration

Patients with impaired oxygen-delivery reserve may warrant treatment at a lower MetHb level than otherwise healthy patients.

Important Methylene Blue Precautions

Methylene blue requires caution in G6PD deficiency because adequate NADPH production is required for its therapeutic action.

It can also cause oxidative hemolysis.

Excessive methylene blue exposure can paradoxically act as an oxidant and worsen methemoglobinemia.

Therefore, repeated treatment should not continue automatically when the patient fails to respond as expected.

Methylene Blue and Serotonin Toxicity

An important modern safety consideration is that methylene blue has monoamine oxidase-A inhibitory activity.

In patients receiving serotonergic medications, it can precipitate serotonin toxicity, particularly with substantial systemic exposure.

When methylene blue is urgently required for life-threatening methemoglobinemia, the immediate oxygen-delivery problem must still be addressed, but serotonergic medications and interaction risk should be reviewed.

When Methylene Blue Fails

Failure to improve should prompt consideration of:

• G6PD deficiency
• Continued oxidant absorption
• Recurrent toxicity from the responsible drug
• Incorrect diagnosis
• Sulfhemoglobinemia
• Inadequate response requiring specialist treatment

Toxicology consultation is particularly useful in refractory cases.

Alternative and Rescue Therapies

For severe methemoglobinemia when methylene blue is contraindicated or ineffective, specialist-directed options can include:

• Ascorbic acid
• Exchange transfusion
• Red-cell transfusion in selected circumstances
• Hyperbaric oxygen as an uncommon rescue strategy

Ascorbic acid reduces methemoglobin relatively slowly and is generally not a substitute for methylene blue in an immediately life-threatening case when methylene blue can safely be used.

Sulfhemoglobinemia

Sulfhemoglobinemia can closely resemble methemoglobinemia.

Features include:

• Persistent cyanosis
• Abnormal dyshemoglobin measurement
• Poor or absent response to methylene blue

Unlike methemoglobin, sulfhemoglobin cannot simply be enzymatically reduced back to normal hemoglobin.

Resolution therefore depends largely on replacement of affected erythrocytes over time.

Decontamination

For dermal exposure:

• Remove contaminated clothing.
• Wash exposed skin thoroughly.

For ingestion, gastrointestinal decontamination is not automatic.

Induced vomiting and routine gastric lavage are outdated approaches.

Activated charcoal may be considered for selected recent ingestions when:

• The causative substance is adsorbed,
• Clinically meaningful exposure occurred, and
• The airway is adequately protected.

Monitoring

Significant cases require:

• Continuous cardiac monitoring
• Respiratory monitoring
• Serial neurologic examinations
• Repeat MetHb measurements
• Assessment for recurrent toxicity

Recurrent measurements are particularly important after exposures such as dapsone, where methemoglobinemia can return after initial improvement.

Prognosis

Most acquired cases have an excellent outcome when:

• The oxidant exposure is stopped
• Tissue hypoxia is recognized promptly
• Appropriate treatment is provided

Severe untreated methemoglobinemia can cause:

• Myocardial ischemia
• Dysrhythmias
• Seizures
• Shock
• Coma
• Death

Key Points

• Methemoglobinemia results from oxidation of hemoglobin iron from Fe²⁺ to Fe³⁺.
• Methemoglobin cannot effectively carry oxygen and also causes a left shift of the remaining oxyhemoglobin dissociation curve.
• Classic causes include benzocaine, dapsone, nitrates/nitrites, aniline compounds, phenazopyridine, primaquine, and inhaled alkyl nitrites.
• Think of methemoglobinemia when there is cyanosis that does not improve as expected with oxygen.
• Blood may appear characteristically chocolate brown.
• Standard pulse oximetry is unreliable and often trends toward approximately 85%.
• PaO₂ can remain normal because it measures dissolved oxygen rather than hemoglobin oxygen-carrying capacity.
• Diagnosis is confirmed with co-oximetry.
• Methylene blue is the standard antidote for clinically significant acquired methemoglobinemia.
• Use methylene blue cautiously in G6PD deficiency, where it may be ineffective and can worsen hemolysis.
• Methylene blue also has MAO-A inhibitory activity and can interact with serotonergic medications.
• Dapsone can cause prolonged or recurrent methemoglobinemia, so continued monitoring may be necessary.
• Failure to respond to methylene blue should raise concern for continued oxidant exposure, G6PD deficiency, or sulfhemoglobinemia.